The role of serum hyaluronic acid determination in the diagnosis of liver fibrosis

• Authors: Monika Gudowska , Bogdan Cylwik , Lech Chrostek
• Languages of publication: EN

Abstracts

EN

The common pathway leading to liver fibrosis and cirrhosis is growing deposition of extracellular matrix (ECM). It results from molecular and histological rearrangement of collagens, glycoproteins and hyaluronans. Hyaluronic acid is a chief component of the extracellular matrix of connective tissues and plays the main structural role in the formation of ECM. The most important organ involved in the synthesis of hyaluronic acid is the liver. In this paper the meaning of hyaluronic acid in the diagnostics of liver diseases is discussed. Here, we focus on the described changes of hyaluronic acid concentration in the pathological processes of the liver, including alcoholic and non-alcoholic liver diseases. The results of published clinical studies have shown its high diagnostic sensitivity, which probably enables its application in laboratory diagnosis.

Keywords

EN

hyaluronic acid; extracellular matrix; non-invasive marker; cirrhosis; fibrosis; hepatitis

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2017
• Volume: 64
• Issue: 3
• Pages: 451-457

Dates

published

2017

received

2016-10-17

revised

2017-01-05

accepted

2017-01-15

(unknown)

2017-07-19

Contributors

author

Monika Gudowska

• Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland

author

Bogdan Cylwik

• Department of Pediatric Laboratory Diagnostics, Medical University of Bialystok, Bialystok, Poland

author

Lech Chrostek

• Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland

References

• Afdhal NH, Nunes D (2004) Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99: 1160-1174. doi: 10.1111/j.1572-0241.2004.30110.x.
• Ali SF, Onaivi ES, Dodd PR, Cadet JL, Schenk S, Kuhar MJ, Koob GF (2011) Understanding the global problem of drug addiction is a challenge for IDARS cientists. Curr Neuropharmacol 9: 2-7. doi: 10.2174/157015911795017245.
• Arain SA, Meo SA, Jamal Q (2011) Serum hyaluronic acid level does not reliably differentiate minimal and significant liver disease in chronic hepatitis C. Saudi Med J 32: 1241-1245.
• Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209-218. doi: 10.1172/JCI24282.
• Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30: 1054-1058. doi: 10.1002/hep.510300409.
• Bierman HR, Hill BR, Reinhardt L, Emory E (1957) Correlation of serum lactic dehydrogenase activity with the clinical status of patients with cancer, lymphomas, and leukemias. Cancer Res 17: 660-667.
• Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344: 495-500. doi: 10.1056/NEJM200102153440706.
• Bullock C (1990) The biochemistry of alcohol metabolism - a brief review. Biochemical Education 18: 62–66.
• Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023. doi: 10.1002/hep.25762.
• Chwist A, Hartleb M, Lekstan A, Kukla M, Gutkowski K, Kajor M (2014) A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study. Pol Arch Med Wewn 124: 704-712 (in Polish).
• Crawford DH, Murphy TL, Ramm LE, Fletcher LM, Clouston AD, Anderson GJ, Subramaniam VN, Powell LW, Ramm GA (2009) Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 49: 418-425. doi: 10.1002/hep.22650.
• Deaciuc IV, McDonough KH, Bagby GJ, Spitzer JJ (1993) Alcohol consumption in rats potentiates the deleterious effect of Gram-negative sepsis on hepatic hyaluronan uptake. Alcohol Clin Exp Res 17: 1002-1008.
• Deaciuc IV, Spitzer JJ, Shellito JE, D'Souza NB (1994) Acute alcohol administration to mice induces hepatic sinusoidal endothelial cell dysfunction. Int Hepat Commun 2: 81-86
• Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M, Smid V, Haluzik M, Bruha R (2014) Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice - an exploratory case-control study. PLoS One 9: e111551. doi: 10.1371/journal.pone.0111551.
• El-Bassiouni NE, Nosseir MM, Madkour ME, Zoheiry MM, Bekheit IW, Ibrahim RA, Ibrahim IM, El Bassiouny AE (2012) Role of fibrogenic markers in chronic hepatitis C and associated hepatocellular carcinoma. Mol Biol Rep 39: 6843-6850. doi: 10.1007/s11033-012-1509-z.
• Fairbanks KD (2012) Alcoholic liver disease http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hepatology/alcoholic-liver-disease/. November 2012
• Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A (2010) Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 51: 500-506. doi: 10.1097/MPG.0b013e3181e376be.
• Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC, HALT-C Trial Group (2008) Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 47: 789-798. doi: 10.1002/hep.22099.
• Geramizadeh B, Janfeshan K, Saberfiroozi M (2008) Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol 14: 174-177. doi: 10.4103/1319-3767.43274.
• Gitlin N, Serio KM (1992) Ischemic hepatitis: widening horizons. Am J Gastroenterol 87: 831-836.
• Gitto S, Villa E (2016) Non-alcoholic fatty liver disease and metabolic syndrome after liver transplant. Int J Mol Sci 17: 490. doi: 10.3390/ijms17040490.
• Gressner AM, Rizk M, Chunfang G, Olav AG (2010) Potential novel biomarkers for monitoring the fibrogenic process in liver. Arab J Gastroenterol 10: S12-S16
• Gudowska M, Gruszewska E, Panasiuk A, Cylwik B, Flisiak R, Świderska M, Szmitkowski M, Chrostek L (2015) Hyaluronic acid concentration in liver diseases. Clin Exp Med 16: 523-528. doi: 10.1007/s10238-015-0388-8.
• Gümüşay O, Ozenirler S, Atak A, Sönmez C, Ozkan S, Tuncel AF, Yılmaz G, Akyol G (2013) Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 43: 228-237. doi: 10.1111/j.1872-034X.2012.01057.x.
• Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, Portal I, Allemand I, Rosenthal-Allieri A, Ouzan D (2005) Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 4: 6. doi: 10.1186/1476-5926-4-6.
• Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF (2002) Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35: 1522-1527. doi: 10.1053/jhep.2002.33638.
• Kaux JF, Samson A, Crielaard JM (2016) Hyaluronic acid and tendon lesions. Muscles Ligaments Tendons J 5: 264-269. doi: 10.11138/mltj/2015.5.4.264.
• Kneeman JM, Misdraji J, Corey KE (2012) Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 5: 199-207. doi: 10.1177/1756283X11430859.
• Korner T, Kropf J, Gressner AM (1996) Serum laminin and hyaluronan in liver cirrhosis markers of progression with high prognostic value. J Hepatol 25: 684-688.
• Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D (2006) Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 12: 3338-3343.
• Lebensztejn DM, Wierzbicka A, Socha P, Pronicki M, Skiba E, Werpachowska I, Kaczmarski M (2011) Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol 58: 563-566.
• Li F, Zhu CL, Zhang H, Huang H, Wei Q, Zhu X, Cheng XY (2012) Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis 16: 9-14.
• McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ (2000) Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 15: 945-951.
• Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA (2008) Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 103: 928-936. doi: 10.1111/j.1572-0241.2007.01761.x.
• Mima K, Beppu T, Ishiko T, Chikamoto A, Nakagawa S, Hayashi H, Watanabe M, Sakamaki K, Baba H (2014) Preoperative serum hyaluronic acid level as a prognostic factor in patients undergoing hepatic resection for hepatocellular carcinoma. Br J Surg 101: 269-276. doi: 10.1002/bjs.9343.
• Mizuno M, Shima T, Oya H, Mitsumoto Y, Mizuno C, Isoda S, Kuramoto M, Taniguchi M, Noda M, Sakai K, Koyama N, Okanoue T (2016) Classification of patients with nonalcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with that using liver histology and other fibrosis markers. Hepatol Res [Epub ahead of print]. doi: 10.1111/hepr.12710.
• Naor D (2016) Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the activity of inflammation and cancer. Front Immunol 7: 39. doi: 10.3389/fimmu.2016.00039.
• Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T (2005) Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 3: 167-174.
• Necas J, Bartosikova L, Brauner P, Kolar J (2008) Hyaluronic acid (hyaluronan): a review. Veterinari Medicina 8: 397-411
• Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571-583. doi: 10.1016/S0140-6736(11)61097-0.
• Nguyen-Khac E, Chatelain D, Decrombecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL (2008) Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 28: 1188-1198. doi: 10.1111/j.1365-2036.2008.03831.x.
• Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, Heeren T, Koziel M, Graham C, Craven DE, Stuver S, Horsburgh CR Jr (2005) HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 40: 538-544.
• Nusgens BV (2010) Hyaluronic acid and extracellular matrix: a primitive molecule? Ann Dermatol Venereol 137: S3-8. doi: 10.1016/S0151-9638(10)70002-8.
• Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ (2012) Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comp Hepatol 11: 5. doi: 10.1186/1476-5926-11-5.
• Peters L, Mocroft A, Soriano V, Resino S, Bellón JM, Asensio C, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD, for EuroSIDA in EuroCoord (2013) Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One 8: e64283. doi: 10.1371/journal.pone.0064283.
• Resino S, Bellón JM, Asensio C, Micheloud D, Miralles P, Vargas A, Catalán P, López JC, Alvarez E, Cosin J, Lorente R, Muñoz-Fernández MA, Berenguer J (2010) Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis 10: 244. doi: 10.1186/1471-2334-10-244.
• Rossi E, Adams LA, Bulsara M, Jeffrey GP (2007) Assessing liver fibrosis with serum marker models. Clin Biochem Rev 28: 3-10.
• Rostami S, Parsian H (2013) Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis. Hepat Mon 13: e13787. doi: 10.5812/hepatmon.13787.
• Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G, Mortality 2000 study group (2005) Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42: 799-805.
• Schanté C, Zuber G, Herlin C, Vandamme TF (2011) Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydrate Polymers 85: 469-489
• Schilsky ML (2013) Hepatitis B '360'. Transplantation Proceedings 45: 982-985.
• Seven G, Karatayli SC, Köse SK, Yakut M, Kabaçam G, Törüner M, Heper AO, Voelker M, Erden E, Bozdayi AM, Uzunalımoğlu O, Bozkaya H, Yurdaydin C (2011) Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol 22: 305-314.
• Shen Y, Shi G, Huang C, Zhu X, Chen S, Sun H, Zhou J, Fan J (2015) Prediction of post-operative liver dysfunction by serum markers of liver fibrosis in hepatocellular carcinoma. PLoS One 10: e0140932. doi: 10.1371/journal.pone.0140932.
• Sowa JP, Heider D, Bechmann LP, Gerken G, Hoffmann D, Canbay A (2013) Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One 8: e62439. doi: 10.1371/journal.pone.0062439.
• Stachowska E, Maciejewska D, Ossowski P, Drozd A, Ryterska K, Banaszczak M, Milkiewicz M, Raszeja-Wyszomirska J, Slebioda M, Milkiewicz P, Jelen H (2013) Apolipoprotein E4 allele is associated with substantial changes in the plasma lipids and hyaluronic acid content in patients with nonalcoholic fatty liver disease. J Physiol Pharmacol 64: 711-717.
• Stickel F, Poeschl G, Schuppan D, Conradt C, Strenge-Hesse A, Fuchs FS, Hofmann WJ, Seitz HK (2003) Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol 15: 945-950.
• Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV (2011) The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One 6: e23218. doi: 10.1371/journal.pone.0023218.
• Voumvouraki A, Koulentaki M, Notas G, Sfakianaki O, Kouroumalis E (2011) Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med 22: 77-83. doi: 10.1016/j.ejim.2010.10.002.
• Yu X, Deng M, Zhang K, Xie XS (2015) Clinical Analysis of 36 Elderly Patients with Schistosome-Induced Liver Disease Complicated by Hepatitis E. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 33: 258-263.

Identifiers

DOI

10.18388/abp.2016_1443